Tuesday, 8 November 2016

Wonkbook: Bernie Sanders thinks this ballot measure could 'spark a national movement'

By Carolyn Y. Johnson The pharmaceutical industry will be closely watching a different tight election race today — a California drug price referendum that has drawn $109 million in opposition funding and could have ripple effects beyond the state if it passes. The ballot initiative, Proposition 61, seeks to piggyback on the prescription drug discounts enjoyed …
 
Wonkbook
The latest economic and domestic policy from Wonkblog
 
 
In this Sept. 19, 2016 photo, backers of the Yes on Proposition 61 measure rally in downtown Los Angeles. The ballot initiative drawing the most spending on the November ballot would not affect the average Californian, but drug companies have a major stake and are spending heavily to defeat it. Proposition 61 would prohibit state agencies from paying more for prescription drugs than the U.S. Dept. of Veterans Affairs does in an effort to curb rising costs for taxpayers. (AP Photo/Alicia Chang)

The ballot initiative drawing the most spending on the November ballot would not affect the average Californian, but drug companies have a major stake and are spending heavily to defeat it. (Alicia Chang/AP)

By Carolyn Y. Johnson

The pharmaceutical industry will be closely watching a different tight election race today — a California drug price referendum that has drawn $109 million in opposition funding and could have ripple effects beyond the state if it passes.

The ballot initiative, Proposition 61, seeks to piggyback on the prescription drug discounts enjoyed by the U.S. Department of Veterans Affairs, requiring most state-funded health insurance programs to pay no more for drugs than VA. The ballot measure affects only drug coverage for a fraction of Californians, who account for about $3.8 billion in drug spending. But its merits and potential unintended consequences have been fiercely debated because of the possibility that the measure could be replicated in other states or trigger more efforts to control drug prices.

Read the rest on Wonkblog.


Chart of the day

The share of national income enjoyed by the wealthiest Americans has continued to increase, indicating increased taxes imposed by President Obama and Congress have not discouraged the rich from working and investing. Max Ehrenfreund has more.

richshare


Top election tweets

ADVERTISEMENT
 

— Matt O'Brien (@ObsoleteDogma) November 8, 2016

 
Most Recent Posts from Wonkblog
The bad things that happen to annoyingly happy people
There's an unfortunate downside to being happy.
 
The little-known reason Americans could be paying too much for chicken
A chicken market index that has guided the supermarket chicken prices for decades has come under scrutiny.
 
A new theory for why Trump voters are so angry — that actually makes sense
"It's absolutely racist to think that black people don't work as hard as white people. So what? We write off a huge chunk of the population as racist and therefore their concerns aren't worth attending to?"
 
Bernie Sanders thinks this state ballot measure to rein in drug prices could ‘spark a national movement’
Proposition 61 would require state agencies to pay no more for drugs than VA does.
 
 
Where legal weed will likely win today — and where it probably won’t
The year's final pot polls are in.
 
It's the one thing Trump and Clinton agree on — and it's probably a fantasy
It's time for presidential candidates to make a new kind of promise.
 
Taxpayers are still bailing out Wall Street, eight years later
Wells Fargo is eligible for up to $1.5 billion in bailout funds over the next seven years. JPMorgan and Bank of America could receive $1.1 billion and $964 million respectively.
 
ADVERTISEMENT
 
Seven things to know about Hillary Clinton and Donald Trump before you vote
The election is on Tuesday. It's time to focus on the issues.
 
He predicted a GOP wave. Now he watches a documentary about blue whales every day.
The godfather of Republican tax policy says Donald Trump erred by not focusing on the economy.
 
The bizarre reason two competing drug prices rose in tandem
There's nothing inherently illegal about it, but legislators are questioning whether it could be a sign of an antitrust violation.
 
 
     
 
©2016 The Washington Post, 1301 K St NW, Washington DC 20071
 
 
 

No comments:

Post a Comment